Results 21 to 30 of about 142 (121)
Antifungal resistance, combinations and pipeline: oh my!
Drugs in Context, 2023 Invasive fungal infections are a strong contributor to healthcare costs, morbidity and mortality, especially amongst hospitalized patients. Historically, Candida was responsible for approximately 15% of all nosocomial bloodstream infections.
Kayla R Stover +4 more
doaj +1 more source
2389. Effect of Rezafungin on QT Interval in Healthy Subjects [PDF]
Open Forum Infectious Diseases, 2018 BACKGROUND: Rezafungin (RZF), a novel, once-weekly echinocandin for treatment and prophylaxis of invasive fungal infections, successfully met safety and efficacy endpoints in Phase 2 and is advancing to Phase 3 studies. RZF is the first echinocandin to undergo a definitive QT evaluation.
Flanagan, Shawn +5 more
openaire +1 more source
Journal of Fungi, 2023 The epidemiology of invasive fungal infections (IFIs) is currently changing, driven by aggressive immunosuppressive therapy, leading to an expanded spectrum of patients at risk of IFIs.
Roya Vahedi-Shahandashti +3 more
doaj +1 more source
Lack of Effect of Rezafungin on QT/QTc Interval in Healthy Subjects [PDF]
Clinical Pharmacology in Drug Development, 2019 AbstractRezafungin is a new echinocandin in development for treatment of candidemia and invasive candidiasis, and for prophylaxis of invasive fungal infections. Rezafungin is the first echinocandin to undergo definitive QT/QTc study. This phase 1, single‐center, randomized, double‐blind trial was conducted to assess effects of intravenous rezafungin vs
Shawn, Flanagan +4 more
openaire +2 more sources
Metabolism, Excretion, and Mass Balance of [ 14 C]-Rezafungin in Animals and Humans
Antimicrobial Agents and Chemotherapy, 2022 Rezafungin is a novel echinocandin being developed for treatment of candidemia and invasive candidiasis and for prevention of invasive fungal disease caused by Candida, Aspergillus , and Pneumocystis spp. in recipients of blood and marrow transplantation. Studies using [
Voon Ong +4 more
openaire +2 more sources
Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review
Journal of Fungi, 2022 The alarming spread and impact of multidrug-resistant Candida auris infections alongside the limited therapeutic options have prompted the development of new antifungals.
Rogelio de J. Treviño-Rangel +5 more
doaj +1 more source
Journal of Fungi, 2022 The isolation of a pan-echinocandin-resistant Candida parapsilosis strain (anidulafungin, caspofungin, micafungin and rezafungin EUCAST MICs > 8 mg/L) from urine of a patient following prolonged exposure to echinocandins (38 days of micafungin followed ...
Maria Siopi +12 more
doaj +1 more source
Rezafungin Prophylactic Efficacy in a Mouse Model of Pneumocystis Pneumonia [PDF]
Biology of Blood and Marrow Transplantation, 2019 Background The risk of Pneumocystis pneumonia often warrants antifungal prophylaxis for bone marrow and solid organ transplantation patients. However, complications such as myelosuppression, nephrotoxicity, and intolerance with the existing standard, TMP/SMX, may hinder or interrupt prophylaxis. Rezafungin (RZF) is a novel echinocandin in development
Melanie Cushion, Alan Ashbaugh
openaire +1 more source
Novel antifungal agents in clinical trials [version 2; peer review: 2 approved]
F1000Research, 2022 Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics.
Samantha E. Jacobs +2 more
doaj +1 more source
Journal of Fungi, 2022 Several new antifungals are currently in late-stage development, including those with novel pharmacodynamics/mechanisms of action that represent new antifungal classes (manogepix, olorofim, ATI-2307, GR-2397). Others include new agents within established
Nathan P. Wiederhold
doaj +1 more source